Trial Profile

A phase II study, multicenter trial to evaluate the efficacy and safety of administering the scheme COMP-14 (cyclophosphamide, vincristine, liposomal doxorubicin-MYOCET and prednisone) combined with rituximab in the treatment of 1st line of patients with non-Hodgkin lymphoma B aggressive and cardiovascular risk. [Estudio fase II, multicetrico para evaluar la eficacia y la seguridad de la administración del esquema COMP-14 (CICLOFOSFAMIDA, VINCRISTINA, DOXORUBICINA LIPOSOMICA-MYOCET Y PREDNISONA) combinado con RITUXIMAB en el tratamiento de 1 linea de pacientes con Linfoma no Hodgkin B agresivo y riesgo cardiovascular]

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide; Doxorubicin liposomal; Methylprednisolone; Prednisone; Rituximab; Vincristine
Indications B-cell lymphoma
Focus Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com